Ipilimumab vs Montelukast
Ipilimumab vs Montelukast: Overview
This comparison examines the pharmacological differences between Ipilimumab and Montelukast.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Montelukast: Selective leukotriene D4 receptor antagonist.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days; Montelukast β 2.7-5.5 hours.
Chemical Properties
Molecular Formula: Montelukast β C35H36ClNO3S.
Molecular Weight: Montelukast β 586.1800 g/mol.
Type: Ipilimumab β Antibody; Montelukast β Small molecule.